Opinion

Video

Dr Lamanna Shares Perspectives on EHA 2024 Data for the 2G BCL2 Inhibitors in R/R CLL

Author(s):

Catherine C. Coombs, MD,Matthew S. Davids, MD, MMSc

Nicole Lamanna, MD, offers expert insights on the emerging data for second-generation BCL2 inhibitors in relapsed/refractory chronic lymphocytic leukemia, highlighting recent advancements in the field.

Video content above is prompted by the following:

  • Briefly share perspective/insights on emerging novel agents in R/R CLL: 2nd gen BCL2 inhibitors 
Related Videos
4 experts are featured in this series.
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
Alexis LeVee, MD
Related Content
Naseema Gangat, MBBS, of Mayo Clinic
January 10th 2025

Novel Agents May Enhance JAK Inhibitor Efficacy and Augment the Myelofibrosis Treatment Paradigm

Alexey Danilov, MD, PhD, Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director, Early Phase Therapeutics Program, the Systems Clinical Trials Office, co-director, Toni Stephenson Lymphoma Center, professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope; Susan M. O'Brien, MD, associate director, Clinical Science, Chao Family Comprehensive Cancer Center, medical director, Sue & Ralph Stern Center for Clinical Trials & Research, professor, medicine, Division of Hematology/Oncology, University of California Irvine School of Medicine
December 31st 2024

Explore the Evolving Role of BTK Inhibitors in CLL: With Alexey Danilov, MD, PhD; and Susan M. O'Brien, MD

Daniel DeAngelo, MD, PhD
January 9th 2025

Blinatumomab Becomes Standard Addition to Consolidation Chemo in B-ALL, Irrespective of MRD Status

Alex F. Herrera, MD, chief, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, associate medical director, Briskin Center for Clinical Research, associate professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
December 13th 2024

Explore Findings With Nivolumab Plus AVD in Advanced-Stage Classic Hodgkin Lymphoma: With Alex F. Herrera, MD

Cancer | Image Credit: © Cornflakesei - stock.adobe.com
January 8th 2025

Dana-Farber Launches Center for RAS Therapeutics to Target the RAS Oncogene in Cancer

Chronic Lymphocytic Leukemia | Image Credit: © LAZLO- stock.adobe.com
January 8th 2025

Fixed-Duration Zanubrutinib/Venetoclax Shows Efficacy in R/R Chronic Lymphocytic Leukemia